Filing Flows › Health Care › Profound Medical (PROF)
Profound Medical (PROF) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 5, 2026 · Profound Medical (PROF) Q3 2026 earnings results →
Q3 2026 Revenue up 86% year over year to $9.8M · 79¢ of every $1 of revenue lost · operating margin -79.6%
Profound Medical made $9.8M in Q3 2026 (+86% Y/Y): Capital equipment $5.7M, Recurring - non-capital $4.1M. Operating margin -79.6%, net loss $7.7M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 5, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $9.8M in Q3 2026, up 86% year over year and up 296% from the previous quarter. Capital equipment was the largest line at 58% of revenue. Capital equipment added $4.5M year over year (up 368%), 99% of the total change.
Gross margin was 78.1%, up 3.8 points from Q3 2025. Operating costs exceeded revenue by $7.8M, an operating margin of -79.6%. Operating expenses grew 21% against revenue growth of 86%. The fastest-growing cost line was SG&A (+31%). The quarter ended with a net loss of $7.7M, narrower than the previous quarter's $9.5M loss.
Operating cash flow was −$5.0M. Non-cash charges added back $133K of depreciation and amortization and $257K of share-based compensation. Working capital and other items added $2.3M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 5, 2026 | $9.8M | +86% | -79.6% | −$7.7M | −$5.0M |
| Q2 2026 | 10-Q | Aug 6, 2026 | $2.5M | +12% | -445.7% | −$9.5M | −$11.3M |
| Q1 2026 | 10-Q | May 7, 2026 | $5.3M | +104% | -150.3% | −$7.1M | −$8.6M |
| Q4 2025 | 10-K | Mar 5, 2026 | $6.0M | +43% | -123.3% | −$8.2M | −$6.6M |
| Q3 2025 | 10-Q | Nov 13, 2025 | $5.3M | +87% | -168.5% | −$8.0M | −$9.6M |
| Q2 2025 | 10-Q | Aug 14, 2025 | $2.2M | -1% | -624.4% | −$15.7M | −$13.7M |
| Q1 2025 | 10-Q | May 8, 2025 | $2.6M | +82% | -426.0% | −$10.7M | −$8.3M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Profound Medical
We are a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue utilizing our platform technologies. Our lead product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. The TULSA-PRO system has been shown in clinical and commercial settings to be an effective tool for physicians who are treating prostate diseases including cancer and other conditions such as benign prostatic hyperplasia (“ BPH ”).
In its own words, from its 10-K, filed Mar 5, 2026.
Profound Medical against its Surgical & Medical Instruments & Apparatus peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +86% against the peers' median +5%. Operating margin: -79.6% against the peers' median 13.3%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| PROF Profound Medical | Q3 2026 | $9.8M | +86% | -79.6% |
| MDLN Medline | Q3 2026 | $7.9B | +10% | 6.4% |
| MMM 3M | Q3 2026 | $6.6B | +1% | 23.7% |
| SYK Stryker | Q3 2026 | $6.5B | +8% | 15.9% |
| BSX Boston Scientific | Q3 2026 | $5.1B | +1% | 16.1% |
| BDX Becton Dickinson | Q3 FY26 | $5.0B | +5% | 13.3% |
| BAX Baxter International | Q3 2026 | $3.0B | +5% | 7.6% |
| SOLV Solventum | Q3 2026 | $1.9B | -7% | 3.5% |
| RMD ResMed | Q1 FY27 | $1.4B | +6% | 32.0% |
Source: Profound Medical 10-Q on SEC EDGAR · CIK 1628808 · Surgical & Medical Instruments & Apparatus
Guidance and outlook
13F: who owns PROF and who is buying
More on PROF
- How Profound Medical makes money: revenue by segment
- Profound Medical next earnings date and what analysts expect
- Profound Medical stock forecast, price target and fair value
- Who owns Profound Medical stock: holders, funds and Congress trades
- Profound Medical guidance and outlook
- Is Profound Medical a takeover target? LBO and rumors
- Profound Medical recalls, complaints and regulation
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results